---
title: "Replimune Group, Inc. (REPL.US) — Company Overview"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/REPL.US/overview.md"
symbol: "REPL.US"
name: "Replimune Group, Inc."
parent: "https://longbridge.com/en/quote/REPL.US.md"
datetime: "2026-04-05T03:03:47.259Z"
locales:
  - [en](https://longbridge.com/en/quote/REPL.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/REPL.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/REPL.US/overview.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/REPL.US/overview.md) | [繁體中文](https://longbridge.com/zh-HK/quote/REPL.US/overview.md)


# Replimune Group, Inc. (REPL.US) — Company Overview

## Basic Information

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Address | 500 Unicorn Park Drive, Suite 303, Woburn, Massachusetts, United States |
| Website | [www.replimune.com](https://www.replimune.com) |

## Company Profile

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells.

## Key Executives

| Name | Title |
|------|-------|
| Sushil Patel | CEO & Director |
| Philip Astley-Sparke | Executive Chairman |
| Emily Luisa Hill | Chief Financial Officer |
| Konstantinos Xynos | Chief Medical Officer |
| Andrew Schwendenman | Chief Accounting Officer & Treasurer |
| Dieter Weinand | Lead Independent Director |
| Joseph P. Slattery | Independent Director |
| Christy J. Oliger | Independent Director |

## Major Shareholders

| Name | Ratio | Report Date |
|------|-------|-------------|
| Baker Bros. Advisors LP | 13.38% | 2025-12-31 |
| T. Rowe Price Group, Inc. | 10.01% | 2025-12-31 |
| RTW Investments, LP | 8.65% | 2025-12-31 |
| BlackRock, Inc. | 7.35% | 2025-12-31 |
| The Vanguard Group, Inc. | 4.57% | 2025-12-31 |
| State Street Global Advisors, Inc. | 4.47% | 2025-12-31 |
| FMR LLC | 3.61% | 2025-12-31 |
| Forbion Capital Partners B.V. | 3.40% | 2025-12-31 |
| D. E. Shaw & Co., L.P. | 3.12% | 2025-12-31 |
| The Toronto-Dominion Bank | 2.70% | 2025-12-31 |


---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**